PharmaLex Group strengthens development consulting team

Friedrichsdorf, Germany-based PharmaLex Group has bolstered its development consulting division with the appointments of Carolyn Belcher and Lutz Wevelsiep.

Belcher (pictured right) joins PharmaLex as executive vice president of development consulting and scientific affairs, bringing over 14 years of regulatory affairs and strategic drug development leadership.

Most recently, Belcher served as head of global regulatory affairs at ICON, having been promoted from vice president in 2014.

She also brings experience from contract research organisation SRA International, where she was senior director and global head of regulatory affairs, and Constella Group, where she was head of strategic drug development services.

Meanwhile, Wevelsiep (pictured left) becomes senior director and principal consultant for development consulting and scientific affairs at PharmaLex, bringing over 25 years of EU and US regulatory affairs expertise.

He has spent the last 16 years of his career as head of global regulatory affairs at Basilea Pharmaceutica, based in Basel, Switzerland, and previously served as group leader for international regulatory affairs at Biogen.

Prior to this, Wevelsiep held a series of increasingly senior regulatory affairs and quality assurance roles at Roche both in Switzerland and the US.

Dr Thomas Dobmeyer, co-chief executive at PharmaLex, said: “It is important that we continue to strengthen our team and both Carolyn and Lutz come to us with a wealth of experience.”

Co-chief executive Dr Tilo Netzer added: “We are in a highly competitive market and having the ability to enhance our service lines with specialists who are at the top of their industry is a key attraction for our clients.”